Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity


We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly… (More)
DOI: 10.1007/s10549-007-9667-8

6 Figures and Tables


  • Presentations referencing similar topics